Scopio Labs Introduces AI-Powered Blood Morphology Automation

Scopio Labs has unveiled its Complete Blood Morphology (CBM) analyzer, an AI-powered solution designed to fully automate blood morphology analysis, announced in a press release. This innovative technology aims to address the global laboratory staffing crisis by analyzing ten times more cells than the current standard, thereby accelerating hematology workflows and improving efficiency.

The CBM analyzer is built on Scopio's proprietary Full-Field technology, which leverages advanced computational imaging and AI-powered analysis. This development transforms the Peripheral Blood Smear (PBS) review process into an autonomous and standardized procedure, eliminating the need for routine human morphology review. The introduction of CBM is expected to reshape the hematology market by providing fully automated results and potentially developing new morphology-based biomarkers and diagnostic panels.

To support the rapid market introduction of CBM, Viola Growth has invested $10 million, extending Scopio's Series D funding to a total of $52 million. Scopio Labs plans to showcase the CBM at the ADLM 2025 Annual Conference in Chicago from July 29-31.